PRINCETON, N. J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Teclison, Inc., a clinical-stage oncology company dedicated to advancing immunotherapeutic treatments for solid tumors, today announced that Ray Lee ...

Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first ...

New global initiative urges patients and clinicians to wait for biomarker testing results before starting treatment.

The one-and-a-half-day symposium will provide an overview of recent advances in the treatment of solid tumors with novel ...

GLP-1 drugs are 36% more effective than aspirin in reducing colorectal cancer risk, with fewer side effects like acute kidney ...

When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, ...

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

Plus Therapeutics will present ReSPECT-LM trial results and host a symposium on leptomeningeal metastases at the SNO/ASCO conference. Announcement of the oral presentation of ReSPECT-LM clinical trial ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.

BullFrog AI's bfLEAP platform identified biomarkers linked to improved survival in pancreatic adenocarcinoma patients treated ...

AI innovations, such as the ASCO Guidelines Assistant, enhance evidence-based decision-making by providing quick access to critical guidelines. ASCO 2025 highlighted breakthroughs, including improved ...